Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics Inc (NQ: EWTX )

28.95 +9.88 (+51.84%)
Streaming Delayed Price Updated: 3:44 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Edgewise Therapeutics Inc

< Previous 1 2 3 Next >
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
From Edgewise Therapeutics
Via Business Wire
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community
From Edgewise Therapeutics
Via Business Wire
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at Upcoming Investor Conferences
From Edgewise Therapeutics
Via Business Wire
Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference
From Edgewise Therapeutics
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.